Factors Influencing the Prescribing Preferences of Physicians for Drug-Naive Patients with Type 2 Diabetes Mellitus in the Real-World Setting in Japan: Insight from a Web Survey

被引：0
|
作者：
Hiroki Murayama
Kota Imai
Masato Odawara
机构：
[1] Novartis Pharma K.K,Medical Division
[2] Tokyo Medical University,Department of Diabetes, Endocrinology, Metabolism, and Rheumatology
来源：
Diabetes Therapy | 2018年 / 9卷
关键词：
Dipeptidyl peptidase-4 inhibitor; Diabetes nonspecialist; Diabetes specialist; Drug-naive; Japan; First line; Metformin; Online survey; Oral antidiabetes drugs; Treatment choices; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1185 / 1199
页数：14
相关论文
共 50 条
  • [21] Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naive Type 2 Diabetes Mellitus: A Randomized Controlled Trial
    Wu, Wenjun
    Li, Ying
    Chen, Xiong
    Lin, Dini
    Xiang, Songying
    Shen, Feixia
    Gu, Xuemei
    MEDICAL SCIENCE MONITOR, 2015, 21 : 2678 - 2684
  • [22] Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
    Gorgojo-Martinez, Juan J.
    Gargallo-Fernandez, Manuel A.
    Sanz-Pastor, Alba Galdon
    Anton-Bravo, Teresa
    Brito-Sanfiel, Miguel
    Wong-Cruz, Jaime
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 18
  • [23] Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT)
    Viswanathan, Vijay
    Singh, K. P.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (08) : 415 - 422
  • [24] Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients
    Silva-Nunes, Jose
    Nascimento, Edite
    Louro, Joana
    Dores, Jorge
    Laginha, Teresa
    Goncalves-Ferreira, Ana
    Alves, Marta
    Souto, Selma B.
    Cunha, Nelson
    Pina, Elsa
    Duarte, Rui
    Raposo, Joao Filipe
    METABOLITES, 2022, 12 (11)
  • [25] Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan
    Takashi Kadowaki
    Nobuya Inagaki
    Hirotaka Watada
    Kazuyo Sasaki
    Kazumi Mori-Anai
    Tomohisa Iwasaki
    Tatsuki Teranishi
    Advances in Therapy, 2022, 39 : 1642 - 1658
  • [26] Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study
    Kim, Hwi Seung
    Cho, Yun Kyung
    Kim, Myung Jin
    Jung, Chang Hee
    Park, Joong-Yeol
    Lee, Woo Je
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [27] Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan
    Kadowaki, Takashi
    Inagaki, Nobuya
    Watada, Hirotaka
    Sasaki, Kazuyo
    Mori-Anai, Kazumi
    Iwasaki, Tomohisa
    Teranishi, Tatsuki
    ADVANCES IN THERAPY, 2022, 39 (04) : 1642 - 1658
  • [28] Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States
    Li, Qian
    Chitnis, Abhishek
    Hammer, Mette
    Langer, Jakob
    DIABETES THERAPY, 2014, 5 (02) : 579 - 590
  • [29] Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
    Ghosh, Sujoy
    Trivedi, Shailesh
    Sanyal, Debmalya
    Modi, K. D.
    Kharb, Sandeep
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2016, 9 : 347 - 353
  • [30] Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for Diabetes ☆
    Swift, Caroline
    Frazer, Monica
    Sargent, Andrew
    Leszko, Michael
    Buysman, Erin
    Gronroos, Noelle N.
    Alvarez, Sara
    Dunn, Tyler J.
    Noone, Josh
    CLINICAL THERAPEUTICS, 2025, 47 (04) : 277 - 283
12345